From the Publisher

Medicine is broken. We like to imagine that it's based on evidence and the results of fair tests. In reality, those tests are often profoundly flawed. We like to imagine that doctors are familiar with the research literature surrounding a drug, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality much of their education is funded by industry. We like to imagine that regulators let only effective drugs onto the market, when in reality they approve hopeless drugs, with data on side effects casually withheld from doctors and patients.

All these problems have been protected from public scrutiny because they're too complex to capture in a sound bite. But Dr. Ben Goldacre shows that the true scale of this murderous disaster fully reveals itself only when the details are untangled. He believes we should all be able to understand precisely how data manipulation works and how research misconduct on a global scale affects us. In his own words, "the tricks and distortions documented in these pages are beautiful, intricate, and fascinating in their details." With Goldacre's characteristic flair and a forensic attention to detail, Bad Pharma reveals a shockingly broken system and calls for something to be done. This is the pharmaceutical industry as it has never been seen before.
Published: Tantor Audio on
ISBN: 9781452611693
Listen on Scribd mobile: iPhone, iPad and Android.
Availability for Bad Pharma by Ben Goldacre and Jonathan Cowley
With a 30 day free trial you can listen to one free audiobook per month

    Related Articles

    Financial Times
    7 min read

    Digital Disrupters Take Big Pharma 'Beyond The Pill'

    After Maggie Philyaw developed Type 2 diabetes, she found solace not in the medicines of the pharmaceutical industry, but the technology of Silicon Valley. Two years ago, her then employer in North Carolina signed Ms Philyaw up to a programme run by Livongo Health, a California-based start-up, which gave her a device, smaller than an iPhone and fitted with a cellular chip, that keeps track of her blood sugar levels. Using the latest advances in cloud computing, the drop of blood she draws each day is instantly analysed, and a text telling her what to do - "drink two glasses of water and walk f
    4 min read

    4 Ways to Shoot Down Skyrocketing Drug Prices

    WHEN POLITICIANS DECRIED the drug company Mylan’s decision to increase the price of an EpiPen by 500% in less than six years, their indignation rang familiar. After all, Congress had just wrapped up a series of hearings examining Valeant Pharmaceuticals’ decision to raise the price of a single vial of its heart medication Isuprel from $180 to $1,472. A few months earlier, Turing Pharmaceuticals CEO Martin Shkreli had been deemed the “most hated man in America” after increasing the price of the antiparasitic drug Daraprim by 5,000% in one month, from $13.50 per pill to $750. Shkreli showed litt
    5 min read

    The High Cost of Lowering Drug Prices the Trump Way

    On the last day in January, President Donald Trump met with chief executives from some of the wealthiest pharmaceutical companies in the United States to discuss the future of their industry. The Oval Office meeting, which was closed to the press after opening remarks, included an issue vital to most people not inside the room: the high price of pharmaceuticals. “We have to get prices down,” the president said in his public introduction. “We have no choice.” He suggested several means toward that end, but veterans of the decades-long battle to lower drug prices say the proposed ideas are unli